UK 356618 is a potent and selective MMP3 inhibitor with IC50 of 5.9 nM, shows >140-fold less potent against MMP-1 (IC50=51000 nM), MMP-2 (IC50=1790 nM), MMP-9 (IC50=840 nM) and MMP-14 (IC50=1900 nM).

UCS15A is a small moelcule SH3 domain-mediated protein-protein interaction blocking agent that inhibits proline-rich ligand-mediated protein-protein interactions (PLPI).

UCPH-102 is a selective, brain penetrant inhibitor of EAAT1 (Excitatory amino acid transporter 1) with IC50 of 420 nM.

UCN-01 (7-Hydroxystaurosporine.

UC-112 is a novel IAP inhibitor that potently inhibits human melanoma (A375 and M14) and human prostate (PC-3 and DU145) cancer cell lines with IC50 of 0.7-3.4 uM.

Ubrogepant (MK-1602) is a novel potent, selective, oral calcitonin gene-related peptide receptor (CGRP) antagonist for acute treatment of migraine..

UBP 296 (UBP296, UBP-296) is a potent, and selective GluR5-subunit containing kainate receptor antagonist with Kd of 1.09 uM.

UBE2M-DCN1 inhibitor 52 is a highly potent inhibitor of DCN1-UBE2M protein-protein interaction with IC50 of 60 nM, inhibits cullin neddylation in pulse-chase NEDD8 transfer assay with EC50 of 80 nM.

UAMC00039 dihydrochloride is a potent inhibitor of dipeptidyl peptidase II (DPP-II) (IC50 = 0.48 nM).

U 19963 is a bioactive compound.

TYK2-IN-30 is a potent, selective and orally active Tyk2 inhibitor with Ki of 0.7 nM, exhibits excellent selectivity (35-fold for JAK1 and 83-fold for JAK3).

Tyclopyrazoflor is an anthranilamide compound with pesticidal activity.

TX2-121-1 is a bivalent hydrophobically tagged adamantane derivative of TX1-85-1, a potent, selective, ATP-competitive Her3 (ErbB3) inhibitor.

Twincretin(Y3298176) is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist

TVP1022 is the S-isomer of rasagiline, which is an anti-Parkinson drug, appears to have the same neuroprotective activity as the R-isomer, but is 1000-fold less active as an MAO-B inhibitor.

Tulathromycin is a new semi-synthetic member of the macrolide group of antibiotics that is recommended for treatment and prevention of bacterial respiratory disease in cattle and pigs.

Tubuloside A is a phenylethanoid glycoside with antioxidative effect and hepatoprotective activity.

TTP-8307 is a potent inhibitor of the replication of several Rhinoviruses and Enteroviruses, targets the nonstructural protein 3A, inhibits the replication of coxsackievirus B3 (CVB3 Nancy) with EC50 of 1.2 uM.

TTP399 (TTP-399) is a hepatoselective, oral Glucokinase (GK) activator with EC50 of 304 nM and 762 nM for human GK at high glucose concentration (15 mM) and normoglycemia (5 mM), respectively.

TTGM 5826 (TTGM5826, TTGM-5826) is a small molecule, potential modulator of tissue transglutaminase (tTG) conformation.

TRX-818 sodium (Foslinanib sodium ) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities, induces cancer cell apoptosis and inhibits cancer cell proliferation.

TRX-0237 Methylate (Hydromethylthionine, Methylene blue) is a Tau aggregation inhibitor (TAI) with Ki of 0.12 uM for intracellular TAI activity.

Troxipide is a novel gastro protective agent with antiulcer, anti-inflammatory and mucus secreting properties.

Trospium Chloride is a competitive muscarinic cholinergic receptor antagonist.

TRO 40303 is a novel cardioprotective compound that delays mitochondrial permeability transition pore (mPTP) opening, binds specifically to TSPO at the cholesterol site (Ki=150 nM).

Triphenyl compound A (TPh A) is a small-molecule inhibitor of nuclear protein Pirin with Kd of 0.6 uM, inhibits the interaction between pirin and Bcl3 in vitro and in cells.

Trimethoprim 3-oxide (Trimethoprim 3-N-oxide) is the primary metabolite of trimethoprim.

Trimetazidine dihydrochloride is a drug for angina pectoris. Trimetazidine is the first cytoprotective anti-ischemic agent , which improves myocardial glucose utilization through inhibition of fatty acid metabolism.

Trigriluzole (BHV-4157) is a novel glutamate modulator for the treatment of mild-to-moderate Alzheimer’s disease (AD).

Triflusal irreversibly inhibits the production of thromboxane-B2 in platelets by acetylating cycloxygenase-1.